Gallic acid [149-91-7]

Référence HY-N0523-500mg

Conditionnement : 500mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2)[1]. Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities[2].

IC50 & Target[1]

COX-2

 

Microbial Metabolite

 

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
[PMID: 27162124]
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
[PMID: 27162124]
A549 IC50
0.4 mM
Compound: Gallic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 27162124]
A549 IC50
100 μM
Compound: GA, Gallic acid
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
[PMID: 23291333]
BV-2 IC50
>50 μM
Compound: 27
Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells
Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells
[PMID: 18926710]
Calu-6 IC50
10 μM
Compound: GA, Gallic acid
Cytotoxicity against human Calu6 cells
Cytotoxicity against human Calu6 cells
[PMID: 23291333]
CCRF-CEM CC50
>250 μM
Compound: 1
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation
[PMID: 25617695]
CCRF-CEM EC50
>50 μM
Compound: 1
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
CCRF-CEM EC50
>50 μM
Compound: 1
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
CCRF-CEM IC50
>200 μM
Compound: GA
Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay
[PMID: 24568614]
CCRF-CEM IC50
>50 μM
Compound: 0, Gallic acid
Cytotoxicity against human CEM cells after 24 hrs by MTT assay
Cytotoxicity against human CEM cells after 24 hrs by MTT assay
[PMID: 18295493]
CCRF-CEM IC50
>50 μM
Compound: 0, Gallic acid
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
[PMID: 18295493]
Epithelial cell IC50
>20 μg/mL
Compound: GA, Gallic acid
Cytotoxicity against rat epithelial cells
Cytotoxicity against rat epithelial cells
[PMID: 23291333]
Erythrocyte IC50
0.59 mM
Compound: 18
Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me
Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me
[PMID: 29631958]
Erythrocyte IC50
0.74 mM
Compound: 18
Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet
Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet
[PMID: 29631958]
Fibroblast IC50
>20 μg/mL
Compound: GA, Gallic acid
Cytotoxicity against rat fibroblast cells
Cytotoxicity against rat fibroblast cells
[PMID: 23291333]
HCT-116 IC50
41.8 μg/mL
Compound: Gallic acid
Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 32731188]
HeLa IC50
26.3 μg/mL
Compound: Gallic acid
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 32731188]
HeLa IC50
358 μM
Compound: GA, Gallic acid
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
[PMID: 23291333]
HL-60 IC50
3.2 μg/mL
Compound: gallic acid
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release
[PMID: 10650074]
HL-60 IC50
300 μM
Compound: GA, Gallic acid
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
[PMID: 23291333]
HUVEC IC50
>294 μM
Compound: 8
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay
[PMID: 37122550]
K562 IC50
33 μM
Compound: GA, Gallic acid
Cytotoxicity against human K562 cells
Cytotoxicity against human K562 cells
[PMID: 23291333]
K562 IC50
4.75 μM
Compound: GA, Gallic acid
Cytotoxicity against human imatinib-resistant K562 cells
Cytotoxicity against human imatinib-resistant K562 cells
[PMID: 23291333]
KB IC50
13.2 μg/mL
Compound: GA, Gallic acid
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 23291333]
L1210 IC50
>50 μM
Compound: 0, Gallic acid
Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
[PMID: 18295493]
L1210 IC50
50 μM
Compound: 0, Gallic acid
Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay
Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay
[PMID: 18295493]
L929 IC50
250 μM
Compound: GA, Gallic acid
Cytotoxicity against mouse L929 cells
Cytotoxicity against mouse L929 cells
[PMID: 23291333]
MCF7 IC50
17.4 μM
Compound: Gallic acid
Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs
Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs
[PMID: 33711444]
P388 ED50
0.7 μg/mL
Compound: Gallic acid
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
[PMID: 3404159]
P388D1 IC50
282 μM
Compound: GA, Gallic acid
Cytotoxicity against human P388D1 cells
Cytotoxicity against human P388D1 cells
[PMID: 23291333]
PLC-PRF-5 IC50
387 μM
Compound: GA, Gallic acid
Cytotoxicity against human PLC/PRF/5 cells
Cytotoxicity against human PLC/PRF/5 cells
[PMID: 23291333]
RAW264.7 IC50
>50 μM
Compound: 13
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay
[PMID: 31419126]
RAW264.7 IC50
631.6 μM
Compound: gallic acid
Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method
Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method
[PMID: 22560043]
RAW264.7 IC50
69.25 μM
Compound: 3a
Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay
Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay
[PMID: 31255924]
Vero IC50
>1 μM
Compound: 0, Gallic acid
Cytotoxicity against african green monkey VERO cells
Cytotoxicity against african green monkey VERO cells
[PMID: 18295493]
Vero IC50
>299 μM
Compound: 0, Gallic acid
Genotoxicity against african green monkey VERO cells
Genotoxicity against african green monkey VERO cells
[PMID: 18295493]
In Vitro

Gallic acid is an antioxidant which can inhibit both COX-2[1]. After 18 h treatment with Gallic acid, the number of viable neutrophils is dramatically decreased from 40.3% to 27.7%, highly comparable with 26.4% for untreated neutrophils. Gallic acid fails to attenuate isoproterenol-induced myocytolysis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The food intake (2.6±0.08 g/day, p=0.69) and the body weight (2.5±0.69 g, p=0.76) of the Gallic acid group do not differ significantly from those of the control group (food intake; 2.41±0.14 g/day and the body weight; 2.83±0.84 g/day). The blood glucose tolerance in the Gallic acid group is significantly improved after 2 weeks of treatment. The blood glucose tolerance of the Gallic acid group after a treatment period of 2 weeks is also significantly better than that of the control group at 90 and 120 min ( p<0.05). The serum triglyceride concentration in the Gallic acid group (0.67±0.03 mM, p<0.05) is significantly reduced relative to that of the control group (1.08±0.20 mM). The total cholesterol concentration is similar in the control (3.19±0.27 mM) and Gallic acid (3.01±0.18 mM) groups[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

170.12

Formule

C7H6O5

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=CC(O)=C(O)C(O)=C1

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (587.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 8.33 mg/mL (48.97 mM; ultrasonic and warming and heat to 60°C)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.8782 mL 29.3910 mL 58.7820 mL
5 mM 1.1756 mL 5.8782 mL 11.7564 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (14.70 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (14.70 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Corn Oil

    Solubility: 20 mg/mL (117.56 mM); Suspended solution; Need ultrasonic

Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
HY-B1659-100mL
 100mL